Janux Therapeutics, Inc. (JANX) financial statements and ratios from SEC XBRL: revenue $10.00M (latest fiscal year), net margin -1136.3%, revenue growth -5.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $10.00M |
| Net Margin | -1136.3% |
| Return on Equity | -11.1% |
| Current Ratio | 16.35 |
| Revenue Growth (YoY) | -5.6% |
| EPS Growth (YoY) | 43.0% |
| FCF Growth (YoY) | 88.5% |
| Price / Book | 1.13 |
| Price / Sales | 43.53 |
| FCF Yield | -4.0% |
| Altman Z-Score | 14.08 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
JANX overview · JANX earnings · JANX KPIs · JANX documents · JANX ownership · JANX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.